Keywords: mgi, forecasts, 1b, peak, sales, novel, thrombocytopenia
MGI forecasts $1B peak US sales for novel thrombocytopenia drug AKR-501
Article | 10 September 2007
MGI Pharma says that AKR-501, the novel, orally-available thrombocytopenia treatment that it has licensed from fellow USA-based biopharmaceutical firm AkaRx, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
